Article Sidebar
Main Article Content
Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review
Main Article Content
Abstract
Abstract: Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point. Despite substantial development in pharmacotherapies for UC in recent years, a significant proportion of patients either fail to respond to treatment or lose their response over the course of the disease. The backbone of disease management in UC is 5-aminosalicylic acid (5-ASA), but patients unresponsive to 5-ASA or with severe disease require advanced therapies including tumor necrosis factor-alpha inhibitors (TNFi), anti-integrins, anti-interleukins and small molecule therapy, Janus kinase (JAK) inhibitors, and S1PR modulators. This review will briefly overview the current state of medical therapeutic options in UC, with further detailing the molecular and clinical aspects of Etrasimod, a sphingosine-1-phosphate receptor (S1PR) modulator.
Cite this article as: Buldukoglu OC, Erzin Y, Cekin AH, Danese S. Etrasimod in treatment of ulcerative colitis: A comprehensive review. Turk J Gastroenterol. 2025;36(6):336-342.
Article Details
References
1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF.
Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. [CrossRef]
2.Törüner M, Ünal NG. Epigenetics of inflammatory bowel diseases.
Turk J Gastroenterol. 2023;34(5):437-448. [CrossRef]
3.Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet.
2023;402(10401):571-584. [CrossRef]
4.Malik TF, Aurelio DM. Extraintestinal manifestations of inflammatory bowel disease. In: StatPearls. Treasure Island (FL): StatPearls
Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/
NBK568797/.
5.Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L.
Acute severe ulcerative colitis trials: the past, the present and the
future. Gut. 2024;73(10):1763-1773. [CrossRef]
6.Lontai L, Kürti Z, Gonczi L, et al. Objective disease monitoring
strategies from a Tertiary Inflammatory Bowel Disease Center in
Hungary. Turk J Gastroenterol. 2023;34(5):508-515. [CrossRef]
7.Fanizza J, Bencardino S, Allocca M, et al. Inflammatory bowel disease and colorectal cancer. Cancers (Basel). 2024;16(17):2943.
[CrossRef]
8.Bokemeyer B, Picker N, Kromer D, Rosin L, Patel H. Rates of clinical
remission and inadequate response to advanced therapies among
patients with ulcerative colitis in Germany. Int J Colorectal Dis.
2023;38(1):116. [CrossRef]
9.Pakdin M, Zarei L, Bagheri Lankarani K, Ghahramani S. The cost of
illness analysis of inflammatory bowel disease. BMC Gastroenterol.
2023;23(1):21. [CrossRef]
10. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining
therapeutic goals for Treat-to-Target. Am J Gastroenterol.
2015;110(9):1324-1338. [CrossRef]
11. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an Update on the
Selecting Therapeutic Targets in Inflammatory Bowel Disease
(STRIDE) Initiative of the International Organization for the Study of
IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. [CrossRef]
12. Fanizzi F, Allocca M, Fiorino G, et al. Raising the bar in ulcerative
colitis management. Therap Adv Gastroenterol.
2024;17:17562848241273066. [CrossRef]
13. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA.
2023;330(10):951-965. [CrossRef]
14. Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative
colitis. Expert Opin Biol Ther. 2020;20(4):363-378. [CrossRef]
15. Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther. 2020;20(4):379-390. [CrossRef]
16. Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A
current overview of corticosteroid use in active ulcerative colitis.
Expert Rev Gastroenterol Hepatol. 2019;13(6):557-561. [CrossRef]
17. Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17(11):1549-1559.
[CrossRef]
18. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, et al. Tumour
necrosis factor inhibitors in inflammatory bowel disease: the story
continues. Therap Adv Gastroenterol. 2021;14:17562848211059954.
[CrossRef]
19. Wetwittayakhlang P, Verdon C, Starr M, et al. Mucosal healing
and clinical efficacy of adalimumab in small intestinal Crohn’s disease (SIMCHA Study): final results from a prospective, open-label,
single-arm study. Turk J Gastroenterol. 2023;34(6):603-610.
[CrossRef]
20.Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety
of vedolizumab for inflammatory bowel disease. Aliment Pharmacol
Ther. 2020;52(8):1353-1365. [CrossRef]
21. Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of
vedolizumab subcutaneous formulation in a randomized trial of
patients with ulcerative colitis. Gastroenterology. 2020;158(3):562-
572.e12. [CrossRef]
22.Afif W, Arasaradnam RP, Abreu MT, et al. Efficacy and safety of
ustekinumab for ulcerative colitis through 4 years: final results of the
UNIFI long-term maintenance Study. Am J Gastroenterol.
2024;119(5):910-921. [CrossRef]
23.Honap S, Agorogianni A, Colwill MJ, et al. JAK inhibitors for
inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2024;15(1):59-69. [CrossRef]
24.Hanzel J, Hulshoff MS, Grootjans J, D’Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18(5):513-
524. [CrossRef]25.Shirley M. Etrasimod: First approval. Drugs. 2024;84(2):247-254.
[CrossRef]
26.Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation
of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16(5):495-503. [CrossRef]
27. Brinkmann V. Sphingosine 1-phosphate receptors in health and
disease: mechanistic insights from gene deletion studies and reverse
pharmacology. Pharmacol Ther. 2007;115(1):84-105. [CrossRef]
28.Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine1-phosphate signaling and its role in disease. Trends Cell Biol.
2012;22(1):50-60. [CrossRef]
29.Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens.
Nature. 1993;365(6446):557-560. [CrossRef]
30.Bryan AM, Del Poeta M. Sphingosine-1-phosphate receptors and
innate immunity. Cell Microbiol. 2018;20(5):e12836. [CrossRef]
31. Tourkochristou E, Mouzaki A, Triantos C. Unveiling the biological
role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases. World J Gastroenterol. 2023;29(1):110-125.
[CrossRef]
32.Vieujean S, Peyrin-Biroulet L. Pharmacokinetics of S1P receptor
modulators in the treatment of ulcerative colitis. Expert Opin Drug
Metab Toxicol. 2024;20(9):881-892. [CrossRef]
33.Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety
of etrasimod in a Phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550-561. [CrossRef]
34.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as
induction and maintenance therapy for ulcerative colitis (ELEVATE):
two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet. 2023;401(10383):1159-1171. Erratum in: Lancet. 2023;
401(10381):1000. [CrossRef]
35.Lichtenstein GR, Allegretti JR, Loftus EV Jr, et al. Assessment and
impact of age on the safety and efficacy of etrasimod in patients
with ulcerative colitis: a post hoc analysis of data from the ELEVATE
UC clinical program. Inflamm Bowel Dis. 2025:izae308. https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/
izae308/8106483?login=false. [CrossRef]
36.Sands BE, Dubinsky MC, Kotze PG, et al. Efficacy and safety of
etrasimod in patients with moderately to severely active ulcerative
colitis stratified by baseline modified mayo score: a post hoc analysis
from the Phase 3 ELEVATE UC clinical program. Inflamm Bowel Dis.
2025:izaf036. https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izaf036/8046180. [CrossRef]
37.Peyrin-Biroulet L, Dubinsky MC, Sands BE, et al. Efficacy and
safety of etrasimod in patients with moderately to severely active
isolated proctitis: results from the Phase 3 ELEVATE UC clinical programme. J Crohns Colitis. 2024;18(8):1270-1282. [CrossRef]
38.Yarur AJ, Chiorean MV, Allegretti JR, et al. Etrasimod as a monotherapy or With Concomitant Use of corticosteroids and/or aminosalicylates: results from the ELEVATE Uc Clinical Program. Inflamm
Bowel Dis. 2024:izae288. https://academic.oup.com/ibdjournal/
advance-article/doi/10.1093/ibd/izae288/7923279?login=false.
[CrossRef]
39.Vermeire S, Sands BE, Peyrin-Biroulet L, et al. Corrigendum to:
Impact of prior biologic or Janus kinase inhibitor therapy on efficacy
and safety of etrasimod in the ELEVATE UC 52 and ELEVATE UC 12
trials. J Crohns Colitis. 2024;18(11):1935-1936. [CrossRef]
40.Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Clinical Guidelines
Committee. Electronic address: clinicalpractice@gastro.org. AGA
Living Clinical Practice Guideline on Pharmacological Management
of Moderate-to-Severe Ulcerative Colitis. Gastroenterology.
2024;167(7):1307-1343.
41. Estevinho MM, Sousa-Pinto B, Moreira PL, et al. Network metaanalysis: histologic and histo-endoscopic improvement and remission with advanced therapy in ulcerative colitis. Aliment Pharmacol
Ther. 2024;60(10):1276-1292. [CrossRef]
42.Jairath V, Rubin DT, Verstockt B, et al. The effect of etrasimod on
fecal calprotectin and high-sensitivity C-reactive protein: results
from the ELEVATE UC clinical program. Inflamm Bowel Dis.
2024:izae111.
43.Yarur AJ, Chiorean MV, Panés J, et al. Achievement of clinical,
endoscopic, and histological outcomes in patients with ulcerative
colitis treated with etrasimod, and association with faecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
J Crohns Colitis. 2024;18(6):885-894. [CrossRef]
44. Vermeire S, Chiorean M, Panés J, et al. Long-term safety and
efficacy of etrasimod for ulcerative colitis: results from the openlabel extension of the OASIS Study. J Crohns Colitis. 2021;15(6):950-
959. [CrossRef]
45.Vermeire S, Rubin DT, Peyrin-Biroulet L, et al. Cardiovascular
events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately
to severely active ulcerative colitis. BMJ Open Gastroenterol.
2025;12(1):e001516. [CrossRef]
46.Regueiro M, Siegmund B, Yarur AJ, et al. Etrasimod for the treatment of ulcerative colitis: analysis of infection events from the ELEVATE UC clinical programme. J Crohns Colitis. 2024;18(10):1596-1605.
[CrossRef]